Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GB263T |
| Synonyms | |
| Therapy Description |
GB263T is an EGFR/cMET/cMET tri-specific antibody, which blocks EGFR and cMET signaling, potentially resulting in inhibition of cell proliferation and tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr LB538). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GB263T | GB-263T|GB 263T | EGFR Antibody 73 MET Antibody 38 | GB263T is an EGFR/cMET/cMET tri-specific antibody, which blocks EGFR and cMET signaling, potentially resulting in inhibition of cell proliferation and tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr LB538). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05332574 | Phase Ib/II | GB263T | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | Unknown status | AUS | 0 |